Oppenheimer Asset Management Inc. Has $536,000 Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Oppenheimer Asset Management Inc. cut its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 53.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,771 shares of the medical instruments supplier’s stock after selling 6,601 shares during the period. Oppenheimer Asset Management Inc.’s holdings in LeMaitre Vascular were worth $536,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. CANADA LIFE ASSURANCE Co boosted its stake in shares of LeMaitre Vascular by 44.7% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock valued at $1,472,000 after purchasing an additional 6,875 shares in the last quarter. Quadrature Capital Ltd boosted its position in LeMaitre Vascular by 129.4% in the first quarter. Quadrature Capital Ltd now owns 22,432 shares of the medical instruments supplier’s stock valued at $1,484,000 after buying an additional 12,654 shares in the last quarter. Janus Henderson Group PLC grew its stake in LeMaitre Vascular by 554.7% during the first quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after buying an additional 47,218 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new stake in shares of LeMaitre Vascular during the second quarter worth approximately $1,010,000. Finally, Harbor Capital Advisors Inc. raised its stake in shares of LeMaitre Vascular by 240.2% in the second quarter. Harbor Capital Advisors Inc. now owns 11,296 shares of the medical instruments supplier’s stock valued at $929,000 after acquiring an additional 7,976 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Oppenheimer restated an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Cantor Fitzgerald started coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price for the company. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 price target on the stock. Barrington Research raised their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Finally, JMP Securities upped their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research report on Tuesday, August 20th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Trading Up 0.2 %

Shares of NASDAQ LMAT opened at $103.74 on Wednesday. LeMaitre Vascular, Inc. has a 1 year low of $51.70 and a 1 year high of $106.49. The firm’s 50-day moving average is $92.45 and its 200-day moving average is $86.15. The firm has a market capitalization of $2.33 billion, a PE ratio of 56.69, a price-to-earnings-growth ratio of 2.50 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.33 EPS. As a group, equities research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.62%. The ex-dividend date is Thursday, November 21st. LeMaitre Vascular’s payout ratio is 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 3,750 shares of the company’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the completion of the sale, the director now directly owns 2,278 shares of the company’s stock, valued at $231,148.66. This represents a 62.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.